(Q46141893)

English

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

scientific article published in July 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

1 reference

Europe PubMed Central

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors (English)

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

neuroendocrine tumor

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/28609356

10

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/28609356

Joseph S Dillon

object named as

Joseph S Dillon

5

0 references

Andrew M Bellizzi

object named as

Andrew M Bellizzi

3

0 references

object named as

James R Howe

11

0 references

Thomas O'Dorisio

object named as

Thomas M O'Dorisio

8

0 references

author name string

Jonathan R Strosberg

1

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Thorvardur R Halfdanarson

2

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Jennifer A Chan

4

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Anthony P Heaney

6

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Pamela L Kunz

7

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Rodney F Pommier

12

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Kari Brendtro

13

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Mohammad A Bashir

14

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Simron Singh

15

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Michael C Soulen

16

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Laura Tang

17

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Jerome S Zacks

18

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

James C Yao

19

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Emily K Bergsland

20

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

publication date

1 July 2017

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

46

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

6

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

707-714

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Carcinoid heart disease: Diagnosis and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Elevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Hepatic-directed Therapies in Patients with Neuroendocrine Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Monitoring of Total and Regional Liver Function after SIRT.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Hepatic neuroendocrine metastases: chemo- or bland embolization?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 July 2018

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Prognostic factors and prevention of radioembolization-induced liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5642985

15 August 2018

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution

1 reference

https://pubmed.ncbi.nlm.nih.gov/28609356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/MPA.0000000000000850

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

1 reference

Europe PubMed Central

13 July 2018

http://europepmc.org/abstract/PMC/5642985

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46141893&oldid=2094320547"